RespireRx Pharmaceuticals Inc (RSPI): gfp927z, I'll need to review Dr. Stoll'...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	4
Posts	153
Boards Moderated	0
Alias Born	10/25/2006

K-G

Re: gfp927z post# 1707

Thursday, 10/26/2006 5:51:15 PM

Thursday, October 26, 2006 5:51:15 PM

gfp927z,
I'll need to review Dr. Stoll's statements also, but I think your assessment is too pessimistic. I thought he implied that for both back-up compounds they did not see a similar cellular toxicity response as with CX-717. I interpret this to mean that they conducted similar dosing level studies (probably in rats)with theses compounds. Perhaps I missed something, and was just looking for something positive...

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent RSPI News

Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM